GlassScriptPhysician profile
Taylor Franklin Smith
NPI 1033348438
$3,930.86
in general payments reported to CMS, 2019-2025
27 companies · $845 in 2025
The $845 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $146 · 2021: $570 · 2022: $650 · 2023: $572 · 2024: $621 · 2025: $845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,037.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,489.42 | 2019-2025 | Clareon, Rocklatan, Total30 |
| Abbvie INC. | $793.62 | 2022-2025 | Durysta, Ozurdex |
| Allergan, INC. | $242.34 | 2019-2021 | |
| Glaukos Corporation | $129.60 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2023 | Eylea Hd |
| Johnson & Johnson Vision Care, INC. | $101.63 | 2019-2021 | |
| Rxsight INC | $101.13 | 2022 | |
| Pfizer INC. | $93.72 | 2020-2021 | |
| Biotissue Holdings INC. | $86.70 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $85.25 | 2025 | Acthar |
| Oyster Point Pharma, INC. | $72.72 | 2023-2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $66.08 | 2019-2021 | |
| Amgen INC. | $61.51 | 2024 | Tepezza |
| Sun Pharmaceutical Industries INC. | $61.15 | 2019-2023 | Cequa |
| Astellas Pharma US INC | $58.40 | 2025 | Veozah |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $55.52 | 2024-2025 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $54.66 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $40.86 | 2024 | Xdemvy |
| Horizon Therapeutics Plc | $39.81 | 2023 | Tepezza |
| Bausch & Lomb Americas INC. | $37.65 | 2024-2025 | Miebo, Vyzulta |
| Astrazeneca Pharmaceuticals LP | $32.46 | 2021 | |
| Kala Pharmaceuticals, INC. | $26.40 | 2021-2022 | |
| Akcea Therapeutics, INC. | $18.94 | 2020 | |
| Shire North American Group INC | $15.51 | 2019 | |
| Ani Pharmaceuticals, INC. | $15.12 | 2022 | |
| Halozyme INC | $13.72 | 2019 | |
| Travere Therapeutics, INC. | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.